FDA, Food and Drug Administration – Communicable Diseases Research

An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines

article

Published on 2023-02-232024-09-05
Journal: Heliyon [Category] update2024,

A pan-serotype antiviral to prevent and treat dengue: A journey from discovery to clinical development driven by public-private partnerships

Article

Published on 2023-02-012024-09-05
Journal: Antiviral research [Category] update2024,

[키워드] ACTIV, an accelerating COVID-19 therapeutic interventions and vaccines ADME, absorption distribution metabolism and excretion BARDA, Biomedical Advanced Research and Development Authority CD3, Center for Drug Design and Discovery COVID-19, Coronavirus disease 2019 Dengue antiviral research and development DENV, dengue virus DVI, dengue vaccine initiative EIF, European Investment Fund FDA, Food and Drug Administration GLP, good laboratory practice GPH, global public health IMI, Innovative Medicines Initiative MMV, Medicines for Malaria Venture MPD, Mectizan® Donation Program NHP, non-human primates NME, new molecular entity NS, non-structural protein NTD, neglected tropical disease PPP, public-private partnership public-private partnership SAR, structure-activity-relationship SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2 TB, Tuberculosis UNITE4TB, academia and industry united innovation and treatment for tuberculosis WHO, World Health Organization
[DOI] 10.1016/j.antiviral.2022.105495 PMC 바로가기 [Article Type] Article

A broad assessment of covid-19 vaccine safety using tree-based data-mining in the vaccine safety datalink

Article

Published on 2022-12-162024-09-04
Journal: Vaccine [Category] 대상포진,

[키워드] ACIP, Advisory Committee on Immunization Practices CDC, Centers for Disease Control and Prevention FDA, Food and Drug Administration ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification VAERS, Vaccine Adverse Event Reporting System VSD, Vaccine Safety Datalink
[DOI] 10.1016/j.vaccine.2022.12.026 PMC 바로가기 [Article Type] Article

Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials

Review

Published on 2022-04-212022-10-04
Journal: International immunopharmacology [Category] COVID19(2023년), SARS, 변종, 임상, 치료제,

[키워드] 2019-nCoV, 2019 novel coronavirus Abstract accompany ACE-2, Angiotensin-Converting Enzyme-2 acute respiratory disease syndrome acute respiratory distress acute respiratory syndrome ADE, Antibody-dependent enhancement adverse effect AE_(s), Adverse effect_(s) AEs approach ARDS ARDS, acute respiratory distress syndrome CAR, Chimeric antigen receptor Cellular Immunotherapy clinical trial Community complementary Convalescent plasma (CP) therapy coronavirus COVID-19 COVID-19 vaccination COVID-19 vaccines COVID-19, Coronavirus disease 2019 CPT, Convalescent plasma therapy CRP, C-reactive protein CRS, Cytokine release syndrome CT_(s), Clinical trial_(s) Cytokine storm Efficacy effort emerging disease epidemiological ESR, Erythrocyte sedimentation rate FCR, Fc receptor FDA, Food and Drug Administration global pandemic GM-CSF, granulocyte-macrophage colony-stimulating factor group GVHD, Graft-versus-host disease HBV, Hepatitis B HCV, Hepatitis C highlight HIV, Human immunodeficiency virus HLH, Hemophagocytic lymphohistiocytosis Human I.V., Intravenous IBD, Inflammatory bowel disease IFN, interferon IGG, immunoglobulin g immunomodulation Immunotherapy Inflammation inhibiting International investigated IVIG, intravenous immunoglobulin LAG-3, Lymphocyte-activation gene 3 LDH, lactate dehydrogenase mAb_(s), Monoclonal antibody_(s) MERS-COV, Middle East respiratory syndrome-corona virus monoclonal antibody MV, Mechanical ventilation Passive Passive immunotherapy PCR, polymerase chain reaction PD-1, Programmed cell death protein-1 platform RA, Rheumatoid arthritis RBD, receptor-binding domain recent reduced SARS-CoV-2 SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 syndrome TIM-3, T cell immunoglobulin domain and mucin domain-3 TNF, Tumor Necrosis Factor TRALI, Transfusion-related acute lung injury treating COVID-19 patient Treatment Vaccine variants of SARS-CoV-2 VEGF, Vascular endothelial growth factor Viral load viral neutralization
[DOI] 10.1016/j.intimp.2022.108786 PMC 바로가기 [Article Type] Review

Effect of monoclonal antibody therapy on the endogenous SARS-CoV-2 antibody response

Article

Published on 2022-02-242023-06-16
Journal: Clinical immunology (Orlando, Fla.) [Category] COVID19(2023년), MERS, SARS,

Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 – a review

Review Article

Published on 2021-12-232023-07-01
Journal: Translational research : the journal of laboratory [Category] COVID19(2023년), SARS,

[키워드] ACE-2, Angiotensin converting enzyme receptor Ad5, Adenovirus type 5 APCs, Antigen Presenting Cells B.1.1.7, Alpha variant B.1.351, Beta variant BAU, binding antibody units BLA, Biologics License Application BMI, Body mass index CDC, Centers for Disease Control COVID-19, Coronavirus disease of 2019 COVID-NET, COVID-19-Associated Hospitalization Surveillance Network CVnCOV, CureVac DCs, dendritic cells DNA, Deoxyribonucleic acid dsRNA, double-stranded RNA EUA, Emergency Use Authorization FDA, Food and Drug Administration GMC, Geometric mean concentration GMT, geometric mean titer LNP, Liposomal nanoparticle MERS-CoV, Middle East respiratory syndrome coronavirus MHC, major histocompatibility complex mRNA, messenger Ribonucleic Acid nAb, neutralizing antibodies PAMPs, pathogen-associated molecular patterns PRNT₅₀, plaque reduction neutralization test RBD, receptor-binding domain SAM, Self-amplifying mRNA SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 tRNA, transfer ribonucleic acid UTR, Untranslated regions VA, Department of Veterans Affairs VAERS, Vaccine Adverse Event Reporting System VE, Vaccine efficacy VOC, variants of concern VSD, Vaccine Safety Datalink
[DOI] 10.1016/j.trsl.2021.12.007 PMC 바로가기 [Article Type] Review Article

Artificial intelligence for the discovery of novel antimicrobial agents for emerging infectious diseases

Article

Published on 2021-11-052023-07-02
Journal: Drug discovery today [Category] COVID19(2023년), SARS,

[키워드] AI, artificial intelligence antimicrobial agents artificial intelligence AVP, Antiviral Peptide COVID-19 DDI, Drug-Drug Interaction DTI, Drug-Target Interaction DUD-E, Database of Useful (Docking) Decoys Enhanced FDA, Food and Drug Administration GAN, Generative Adversarial Network Infectious diseases SARS-CoV-2, Severe Acute Respiratory Syndrome-Associated Coronavirus 2
[DOI] 10.1016/j.drudis.2021.10.022 PMC 바로가기

SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies

Review

Published on 2021-10-162022-10-04
Journal: International immunopharmacology [Category] MERS, SARS, 변종, 신약개발, 유전자 메커니즘,

[키워드] Abstract ACE-2, Angiotensin-converting enzyme 2 AKI, acute kidney injury Ang II, Angiotensin II BALF, Broncho alveolar lavage fluid cGMP, Good Manufacturing Practice Characteristics coronavirus disease 19 COVID-19 COVID-19 infection COVID-19, Coronavirus disease of 2019 CRISPR, Clustered Regularly Interspaced Short Palindromic Repeats CRS, Cytokine release syndrome CT, Computed tomography CT, Cycle threshold current Cytokine storm DENV, dengue virus develop diagnostic tests dimension drugs emerging variants FDA, Food and Drug Administration FNR, False‐negative rate Genome GGOs, Ground-glass opacities global effort HAT, Human airway trypsin-like protease health emergency Health Organization HIV, Human immunodeficiency virus IBV, infectious bronchitis virus ICU, Intensive care unit IL, interleukin immune response immune responses Immunity include Infection International JEV, Japanese encephalitis virus lack LAMP, Loop-mediated isothermal amplification LF, Lactoferrin mechanism MIP1α, Macrophage inflammatory protein 1α MRI, Magnetic resonance imaging MSC, Mesenchymal Stem Cells Mutation mutations NCD, Newcastle disease virus new virus NP, nasopharyngeal NSPs, Nonstructural proteins OP, Oropharyngeal pandemic Pathogenesis pathogenicity Potential treatment Prevent problem RAS, Renin-angiotensin system RBD, Receptor binding-domain RdRp, RNA-dependent RNA polymerases Reinfection Research resulting SARS-CoV SARS-CoV-2 SARS-COV-2, severe acute respiratory syndrome coronavirus-2 severity TGF, Transforming growth factor Th17, T helper 17 the disease the SARS-CoV-2 therapeutic therapy Transmissibility treat Vaccine vaccine candidate Vaccine development Vaccines variant variants variants of SARS-CoV-2 virus VLPs, Virus-like particles VTM, Viral transport medium while WHO WNV, West Nile virus
[DOI] 10.1016/j.intimp.2021.108232 PMC 바로가기 [Article Type] Review

Targeting purinergic receptors to suppress the cytokine storm induced by SARS-CoV-2 infection in pulmonary tissue

Article

Published on 2021-09-132022-11-01
Journal: International immunopharmacology [Category] COVID-19, MERS, SARS,

[키워드] “cytokine storm” A1, adenosine 1 receptor A2A, adenosine 2A receptor A2B, adenosine 2B receptor A3, adenosine 3 receptor Abstract ACE2 ACE2, angiotensin II-converting enzyme ACh, Acetylcholine Activation acute respiratory syndrome ADA, adenosine deaminase adenosine Ado, adenosine nucleoside ADP, adenosine diphosphate AEC, alveolar epithelial cell AK, adenosine kinase ALP, alkaline phosphatases alveolar epithelial cell AM, alveolar macrophages AMP, adenosine monophosphate APC, antigen presenting cell ARDS, acute respiratory distress syndrome ATP ATP, adenosine triphosphate binding CCL, chemokine ligand with CC motif CD, cluster of differentiation CDC, Centers for Disease Control and Prevention characterized CLR, C-type lectin receptor CNS, Central Nervous System CNT, concentrated nucleoside transporters COPD, Chronic obstructive pulmonary disease coronavirus coronavirus disease cough COVID-19 COVID-19, coronavirus disease CT, Computed tomography cytokine DAMP, danger-associated molecular pattern death Defense difficulty breathing E protein, envelope protein E-5′-NT, ecto-5′-nucleotidase E-NPP, ectonucleotide pyrophosphatase/ phosphodiesterase E-NTPDase, ectonucleoside triphosphate diphosphohydrolase effective ENT, balanced nucleoside transporters enzyme etiological agent expressed FDA, Food and Drug Administration Fever G-CSF, granulocyte colony-stimulating factor GABA, γ-amino butyric acid GVHD, Graft-versus-host disease H1N1, influenza type A subtype H1N1 virus HIF, hypoxia-inducible factor ICTV, International Committee on Taxonomy of Viruses ICU, Intensive care unit IFN-γ, interferon gamma IFN-I, type I interferon IGG, immunoglobulin g IGM, immunoglobulin m IL-1β, interleukin 1 beta IL, interleukin immune immune cells immune system infecting Infection Inflammation Interaction involved IP-10, interferon gamma-induced protein 10 IPF, Idiopathic pulmonary fibrosis Lung disease M protein, membrane protein MCP-1, monocyte chemotactic protein 1 mechanism MERS-CoV, Middle East respiratory syndrome MHC-I, major histocompatibility complex class I MHC-II, major histocompatibility complex class II MIP-1α, macrophage inflammatory proteins 1-alpha modulation N protein, nucleocapsid protein NAc, nucleus accumbens NET, neutrophil extracellular traps NK, natural killer NLRP3, NOD-, LRR- and pyrin domain-containing protein 3 organ P1, type 1 purinergic receptor P2, type 2 purinergic receptor P2X7 pandemic Pneumonia Protein purinergic signaling receptor receptors reduce Replication respiratory tract responsible RNA, Ribonucleic acid ROS, reactive oxygen species RT-PCR, Reverse transcription polymerase chain reaction S protein, spike protein SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 virus SARS-CoV, severe acute respiratory syndrome coronavirus SARS, Severe acute respiratory syndrome severity Signaling single-stranded RNA virus suppress targeting the Coronaviridae the cytokine storm the disease therapy tissue TNF-α, tumor necrosis factor alpha Treatment Trigger viral surface virus WHO, World Health Organization with COVID-19
[DOI] 10.1016/j.intimp.2021.108150 PMC 바로가기 [Article Type] Article

Recent advances in management of COVID-19: A review

Review

Published on 2021-08-272023-06-16
Journal: Biomedicine & pharmacotherapy = Biomédecine & phar [Category] MERS, SARS,

[키워드] LPS, Lipopolysaccharides MERS, Middle East Respiratory Syndrome 1KD, Equilibrium dissociation constant (binding affinity) ADE, Antibody dependant enhancement of the disease ARDS, acute respiratory distress syndrome CDC, Centers for Disease Control and Prevention CoV, coronavirus COVID-19 COVID-19, coronavirus disease-2019 CVT, Cerebral Venous Thrombosis Dexamethasone EC50, half maximum neutralization concentration EUA, Emergency Use Authorization Famotidine FDA, Food and Drug Administration Fluoxetine fluvoxamine IC50, Half maximal inhibitory concentration IC90, Concentration that inhibits 90% of the virions ICU, Intensive care unit IL-6, interleukin 6 IMP, importin IRE1, Inositol-requiring enzyme Ivermectin melatonin monoclonal antibodies nanobodies Nbs, Nanobodies NEJM, The New England Journal of Medicine NIH, National Institutes of Health NOS, Reactive nitrogen species OTC, Over the Counter medication PCR, polymerase chain reaction RBD, receptor binding domain RdRp, RNA-dependent RNA polymerase Remdesivir ROS, reactive oxygen species S1R, Sigma 1 receptor SARS-CoV-2 SARS-CoV-2, Severe Acute Respiratory Syndrome Corona Virus 2 SARS, Severe acute respiratory syndrome sdNbs, Single domain nanobodies Serotonin SPR, surface plasmon resonance SSRI TMPRSS2, Transmembrane serine protease 2 TNF-alpha, Tumor Necrosis Factor alpha Tocilizumab WHO, World Health Organization
[DOI] 10.1016/j.biopha.2021.112107 PMC 바로가기 [Article Type] Review